Development of an apolipoprotein E mimetic peptide–lipid conjugate for efficient brain delivery of liposomes

References

• Bach A, Clausen BH, Møller M, et al. (2012). A high-affinity, dimeric inhibitor of PSD-95 bivalently interacts with PDZ1-2 and protects against ischemic brain damage. Proc Natl Acad Sci U S A 109:1–10.
   Web of Science ®Google Scholar
• Bana L, Minniti S, Salvati E, et al. (2014). Liposomes bi-functionalized with phosphatidic acid and an ApoE-derived peptide affect Aβ aggregation features and cross the blood–brain-barrier: implications for therapy of Alzheimer disease. Nanomedicine 10:1583–90.
   PubMed Web of Science ®Google Scholar
• Couch JA, Yu YJ, Zhang Y, et al. (2013). Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier. Sci Transl Med 5:183ra57.
   PubMed Web of Science ®Google Scholar
• Demeule M, Régina A, Ché C, et al. (2008). Identification and design of peptides as a new drug delivery system for the brain. J Pharmacol Exp Ther 324:1064–72.
   PubMed Web of Science ®Google Scholar
• Eigenmann DE, Xue G, Kim KS, et al. (2013). Comparative study of four immortalized human brain capillary endothelial cell lines, hCMEC/D3, hBMEC, TY10, and BB19, and optimization of culture conditions, for an in vitro blood–brain barrier model for drug permeability studies. Fluids Barriers CNS 10:33.
   PubMedGoogle Scholar
• Fumoto S, Kinoshita E, Ohta K, et al. (2020). A pH-adjustable tissue clearing solution that preserves lipid ultrastructures: suitable tissue clearing method for DDS evaluation. Pharmaceutics 12:1070.
   PubMed Web of Science ®Google Scholar
• Gaillard PJ, Appeldoorn CCM, Dorland R, et al. (2014). Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101). PLoS One 9:e82331.
   PubMed Web of Science ®Google Scholar
• Gao H. (2016). Progress and perspectives on targeting nanoparticles for brain drug delivery. Acta Pharm Sin B 6:268–86.
   PubMed Web of Science ®Google Scholar
• Grafals-Ruiz N, Rios-Vicil CI, Lozada-Delgado EL, et al. (2020). Brain targeted gold liposomes improve rnai delivery for glioblastoma. Int J Nanomedicine 15:2809–28.
   PubMed Web of Science ®Google Scholar
• Hagimori M, Chinda Y, Suga T, et al. (2018). Synthesis of high functionality and quality mannose-grafted lipids to produce macrophage-targeted liposomes. Eur J Pharm Sci 123:153–61.
   PubMed Web of Science ®Google Scholar
• Huwyler J, Wu D, Pardridge WM. (1996). Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci U S A 93:14164–9.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Zhang J, Meng F, Zhong Z. (2018). Apolipoprotein E peptide-directed chimeric polymersomes mediate an ultrahigh-efficiency targeted protein therapy for glioblastoma. ACS Nano 12:11070–9.
   PubMed Web of Science ®Google Scholar
• Kato N, Sato T, Fuchigami Y, et al. (2022). Synthesis and evaluation of a novel adapter lipid derivative for preparation of cyclic peptide-modified PEGylated liposomes: application of cyclic RGD peptide. Eur J Pharm Sci 176:106239.
   PubMed Web of Science ®Google Scholar
• Kawakami S, Suga T. (2020). Development of Nano-DDS carriers for control of spatial distribution using multi-color deep imaging. Yakugaku Zasshi 140:633–40.
   PubMed Web of Science ®Google Scholar
• Kristensen M, Kucharz K, Felipe Alves Fernandes E, et al. (2020). Conjugation of therapeutic PSD-95 inhibitors to the cell-penetrating peptide tat affects blood–brain barrier adherence, uptake, and permeation. Pharmaceutics 12:661.
   PubMed Web of Science ®Google Scholar
• Kucharz K, Kristensen K, Johnsen KB, et al. (2021). Post-capillary venules are the key locus for transcytosis-mediated brain delivery of therapeutic nanoparticles. Nat Commun 12:4121.
   PubMed Web of Science ®Google Scholar
• Kumar V, Patiyal S, Kumar R, et al. (2021). B3Pdb: an archive of blood–brain barrier-penetrating peptides. Brain Struct Funct 226:2489–95.
   PubMed Web of Science ®Google Scholar
• Kumthekar P, Tang S-C, Brenner AJ, et al. (2020). ANG1005, a brain-penetrating peptide–drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases. Clin Cancer Res 26:2789–99.
   PubMed Web of Science ®Google Scholar
• Lee JH, Engler JA, Collawn JF, Moore BA. (2001). Receptor mediated uptake of peptides that bind the human transferrin receptor. Eur J Biochem 268:2004–12.
   PubMedGoogle Scholar
• Lehtinen J, Magarkar A, Stepniewski M, et al. (2012). Analysis of cause of failure of new targeting peptide in PEGylated liposome: molecular modeling as rational design tool for nanomedicine. Eur J Pharm Sci 46:121–30.
   PubMed Web of Science ®Google Scholar
• Li Y, Song Y, Zhao L, et al. (2008). Direct labeling and visualization of blood vessels with lipophilic carbocyanine dye DiI. Nat Protoc 3:1703–8.
   PubMed Web of Science ®Google Scholar
• Libeu CP, Lund-Katz S, Phillips MC, et al. (2001). New Insights into the heparan sulfate proteoglycan-binding activity of apolipoprotein E. J Biol Chem 276:39138–44.
   PubMed Web of Science ®Google Scholar
• Matsui T, Yoshino A, Tanaka M. (2020). A trip of peptides to the brain. Food Prod Process and Nutr 2:30.
   Google Scholar
• Morito T, Harada R, Iwata R, et al. (2021). Synthesis and pharmacokinetic characterisation of a fluorine-18 labelled brain shuttle peptide fusion dimeric affibody. Sci Rep 11:2588.
   PubMed Web of Science ®Google Scholar
• Nag O, Awasthi V. (2013). Surface engineering of liposomes for stealth behavior. Pharmaceutics 5:542–69.
   PubMedGoogle Scholar
• Niewoehner J, Bohrmann B, Collin L, et al. (2014). Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron 81:49–60.
   PubMed Web of Science ®Google Scholar
• Ogawa K, Fuchigami Y, Hagimori M, et al. (2018). Efficient gene transfection to the brain with ultrasound irradiation in mice using stabilized bubble lipopolyplexes prepared by the surface charge regulation method. IJN 13:2309–20.
   Google Scholar
• Ogawa K, Kato N, Kawakami S. (2020). Recent strategies for targeted brain drug delivery. Chem Pharm Bull (Tokyo) 68:567–82.
   PubMed Web of Science ®Google Scholar
• Oller-Salvia B, Sánchez-Navarro M, Giralt E, Teixidó M. (2016). Blood–brain barrier shuttle peptides: an emerging paradigm for brain delivery. Chem Soc Rev 45:4690–707.
   PubMed Web of Science ®Google Scholar
• Re F, Cambianica I, Zona C, et al. (2011). Functionalization of liposomes with ApoE-derived peptides at different density affects cellular uptake and drug transport across a blood-brain barrier model. Nanomedicine 7:551–9.
   PubMed Web of Science ®Google Scholar
• Rousselle C, Clair P, Lefauconnier J-M, et al. (2000). New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. Mol Pharmacol 57:679–86.
   PubMed Web of Science ®Google Scholar
• Ruan S, Zhou Y, Jiang X, Gao H. (2021). Rethinking CRITID procedure of brain targeting drug delivery: circulation, blood brain barrier recognition, intracellular transport, diseased cell targeting, internalization, and drug release. Adv Sci (Weinh) 8:2004025.
   PubMedGoogle Scholar
• Sauer I, Dunay IR, Weisgraber K, et al. (2005). An apolipoprotein E-derived peptide mediates uptake of sterically stabilized liposomes into brain capillary endothelial cells. Biochemistry 44:2021–9.
   PubMed Web of Science ®Google Scholar
• Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. (1999). In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285:1569–72.
   PubMed Web of Science ®Google Scholar
• Suga T, Fuchigami Y, Hagimori M, Kawakami S. (2017). Ligand peptide-grafted PEGylated liposomes using HER2 targeted peptide-lipid derivatives for targeted delivery in breast cancer cells: the effect of serine-glycine repeated peptides as a spacer. Int J Pharm 521:361–4.
   PubMedGoogle Scholar
• Suga T, Kato N, Hagimori M, et al. (2018). Development of high-functionality and -quality lipids with RGD peptide ligands: application for PEGylated liposomes and analysis of intratumoral distribution in a murine colon cancer model [research-article]. Mol Pharmaceutics 15:4481–90.
   PubMed Web of Science ®Google Scholar
• Urich E, Schmucki R, Ruderisch N, et al. (2015). Cargo delivery into the brain by in vivo identified transport peptides. Sci Rep 5:14104.
   PubMed Web of Science ®Google Scholar
• Uwamori H, Ono Y, Yamashita T, et al. (2019). Comparison of organ-specific endothelial cells in terms of microvascular formation and endothelial barrier functions. Microvasc Res 122:60–70.
   PubMed Web of Science ®Google Scholar
• van Rooy I, Mastrobattista E, Storm G, et al. (2011). Comparison of five different targeting ligands to enhance accumulation of liposomes into the brain. J Control Release 150:30–6.
   PubMed Web of Science ®Google Scholar
• Wang D, El-Amouri SS, Dai M, et al. (2013). Engineering a lysosomal enzyme with a derivative of receptor-binding domain of apoE enables delivery across the blood–brain barrier. Proc Natl Acad Sci U S A 110:2999–3004.
   PubMed Web of Science ®Google Scholar
• Weksler B, Romero IA, Couraud P-O. (2013). The hCMEC/D3 cell line as a model of the human blood brain barrier. Fluids Barriers CNS 10:16.
   PubMedGoogle Scholar
• Yao H, Wang K, Wang Y, et al. (2015). Enhanced blood–brain barrier penetration and glioma therapy mediated by a new peptide modified gene delivery system. Biomaterials 37:345–52.
   PubMed Web of Science ®Google Scholar
• Yasaswi PS, Shetty K, Yadav KS. (2021). Temozolomide nano enabled medicine: promises made by the nanocarriers in glioblastoma therapy. J Control Release 336:549–71.
   PubMed Web of Science ®Google Scholar
• Zhan C, Li B, Hu L, et al. (2011). Micelle-based brain-targeted drug delivery enabled by a nicotine acetylcholine receptor ligand. Angew Chem Int Ed Engl 50:5482–5.
   PubMed Web of Science ®Google Scholar